



PG5043USw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of: Boyd et al.

US National Serial No: 10/538,133

Filed: June 9, 2005

Title: 5-Hydroxytryptamine Transporter Gene Polymorphisms

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH  
37 C.F.R. § 1.821-1.825

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821 (g), does not include new matter;
2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821 (c) and (e), respectively, are the same; and
3. all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.


Respectfully submitted

3 Feb. 2006  
Date

  
Virginia G. Campen  
Attorney of Record, Reg. No. 37,092

GlaxoSmithKline  
Corporate Intellectual Property Department  
Five Moore Drive, PO Box 13398  
Research Triangle Park, NC 27709-3398 US  
Phone: 919-483-1012  
Facsimile: 919-483-7988

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450" under 37 CFR 1.8(a) on 2/3/2006

  
Patty Wilson